Friday, October 21, 2022

Powering All of Us with the NIH, Vanderbilt University, and The Broad Institute

Powering All of Us with the NIH, Vanderbilt University, and The Broad Institute

What is All of Us?

All of Us is a precision health initiative, led by the National Institutes of Health (NIH), that aims to collect multimodal data from more than 1 million people in the U.S. to advance biomedical research. In collaboration with Verily, Vanderbilt University Medical Center and the Broad Institute of MIT and Harvard, All of Us is empowering health experts to derive real-world evidence from an unprecedented amount of data—improving our ability to prevent, treat & diagnose human diseases. Researchers currently have access to data on over 350,000 participants, including whole genome sequences from almost 100,000.

Why All of Us?

Our ability to achieve precision health — care that is personalized, patient-centered, and accessible — will depend on new ways of generating the evidence. If our research programs continue to lack representation from diverse patient populations, research findings will continue to lack generalizability. It is our responsibility to harness our technologies to drive more representation to provide better applicability for research findings. This ethos is the driving force behind our ongoing efforts with the NIH and as of June 2022, All of Us has consented 500k+ people, nearly 80% of whom identify with a community or group historically underrepresented in medical research.


Our Approach

The All of Us Researcher Workbench is supported by a vibrant research community and  powered by Terra, a cloud-agnostic biomedical research platform jointly built by The Broad, Microsoft, and Verily. The Researcher Workbench enables secure access to the multimodal data collected through the program, empowering researchers with cloud-based analysis tools for collaborative research.

Join Us

Sign up at to access the Terra Workbench & join the community of researchers working to accelerate scientific discovery & advance the development of novel treatments.